Erectile dysfunction in patients with type 2 diabetes predicts coronary heart disease

Obesity is the cause of a number of diseases such as type 2 diabetes, hypertension, atherosclerosis and coronary heart disease [1]. Obesity is associated with the development of a number of hormone-dependent tumors (breast cancer, uterine cancer) and colon cancer [2]. Metabolic and hormonal disorders that accompany obesity and underlying a number of diseases, including may have an impact on erectile function. Despite the fact that in the literature there are few publications on the relationship of obesity and erectile dysfunction (ED), we could not find work on the effectiveness of treatment of patients with erectile dysfunction and obesity. These large-scale research on the role of weight loss in the treatment of other diseases, such as such as type 2 diabetes, hypertension, coronary heart disease, suggest that weight control and related metabolic disorders are able to provide a significant improvement in erectile quality function and effectiveness of the treatment of ED [3, 4, 5, 6].

Download Full-text

Erectile dysfunction predicts coronary heart disease in patients with type 2 diabetes

Nature Clinical Practice Urology ◽

10.1038/ncpuro1160 ◽

2008 ◽

Vol 5 (8) ◽

pp. 410-411

Keyword(s):

Type 2 Diabetes ◽

Coronary Heart Disease ◽

Heart Disease ◽

Erectile Dysfunction

Download Full-text

2436-PUB: Predicting Risk for New-Onset Type 2 Diabetes in Chinese People with Coronary Heart Disease and Impaired Glucose Tolerance

Diabetes ◽

10.2337/db19-2436-pub ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 2436-PUB

Author(s):

SHISHI XU ◽

CHARLES A. SCOTT ◽

RUTH L. COLEMAN ◽

JAAKKO TUOMILEHTO ◽

RURY R. HOLMAN

Keyword(s):

Type 2 Diabetes ◽

Coronary Heart Disease ◽

Heart Disease ◽

Glucose Tolerance ◽

Impaired Glucose Tolerance ◽

Chinese People ◽

Onset Type ◽

New Onset

Download Full-text

Mutations of mtDNA in some vascular and metabolic diseases

Current Pharmaceutical Design ◽

10.2174/1381612826999200820162154 ◽

2020 ◽

Vol 26 ◽

Author(s):

Margarita A. Sazonova ◽

Anastasia I. Ryzhkova ◽

Vasily V. Sinyov ◽

Marina D. Sazonova ◽

Tatiana V. Kirichenko ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Coronary Heart Disease ◽

Type 2 Diabetes Mellitus ◽

Heart Disease ◽

Chronic Diseases ◽

Metabolic Diseases ◽

Present Review ◽

Mtdna Mutations

Background: The present review article considers some chronic diseases of vascular and metabolic genesis, the causes of which may be mitochondrial dysfunction. Very often, in the long course of the disease, complications may occur, leading to myocardial infarction or ischemic stroke and as a result, death.In particular, a large percentage of human deaths nowadays belongs to cardiovascular diseases such as coronary heart disease (CHD), arterial hypertension, cardiomyopathies and type 2 diabetes mellitus. Objective: The aim of the present review was the analysis of literature sources, devoted to an investigation of a link of mitochondrial DNA mutations with chronic diseases of vascular and metabolic genesis, Results: The analysis of literature indicates the association of the mitochondrial genome mutations with coronary heart disease, type 2 diabetes mellitus, hypertension and various types of cardiomyopathies. Conclusion: The detected mutations can be used to analyze the predisposition to chronic diseases of vascular and metabolic genesis. They can also be used to create molecular-cell models necessary to evaluate the effectiveness of drugs developed for treatment of these pathologies. MtDNA mutations associated withthe absence of diseases of vascular and metabolic genesis could be potential candidates for gene therapy of diseases of vascular and metabolic genesis.

Download Full-text

Correction to: Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study

Cardiovascular Diabetology ◽

10.1186/s12933-021-01269-8 ◽

2021 ◽

Vol 20 (1) ◽

Author(s):

Elena M. Yubero-Serrano ◽

Juan F. Alcalá-Diaz ◽

Francisco M. Gutierrez-Mariscal ◽

Antonio P. Arenas-de Larriva ◽

Patricia J. Peña-Orihuela ◽

...

Keyword(s):

Type 2 Diabetes ◽

Coronary Heart Disease ◽

Heart Disease ◽

Peripheral Artery Disease ◽

Cholesterol Efflux ◽

Peripheral Artery ◽

Cholesterol Efflux Capacity ◽

Artery Disease

An amendment to this paper has been published and can be accessed via the original article.

Download Full-text

A retrospective study on the usefulness of the JJ risk engine for predicting the incidence rate of coronary heart disease in type 2 diabetes patients

BMC Research Notes ◽

10.1186/s13104-021-05508-9 ◽

2021 ◽

Vol 14 (1) ◽

Author(s):

Yasunari Yamashita ◽

Rina Kitajima ◽

Kiyoshi Matsubara ◽

Gaku Inoue ◽

Hajime Matsubara

Keyword(s):

Type 2 Diabetes ◽

Coronary Heart Disease ◽

Heart Disease ◽

Medical Records ◽

Low Frequency ◽

University Hospital ◽

Diabetes Treatment ◽

C Statistic ◽

Risk Engine

Abstract Objective In 2018, we conducted a retrospective survey using the medical records of 484 patients with type 2 diabetes. The observed value of coronary heart disease (CHD) incidence after 5 years and the predicted value by the JJ risk engine as of 2013 were compared and verified using the discrimination and calibration values. Results Among the total cases analyzed, the C-statistic was 0.588, and the calibration was p < 0.05; thus, the JJ risk engine could not correctly predict the risk of CHD. However, in the group expected to have a low frequency of hypoglycemia, the C-statistic was 0.646; the predictability of the JJ risk engine was relatively accurate. Therefore, it is difficult to accurately predict the complication rate of patients using the JJ risk engine based on the diabetes treatment policy after the Kumamoto Declaration 2013. The JJ risk engine has several input items (variables), and it is difficult to satisfy them all unless the environment is well-equipped with testing facilities, such as a university hospital. Therefore, it is necessary to create a new risk engine that requires fewer input items than the JJ risk engine and is applicable to several patients.

Download Full-text